Insulin Delivery Devices Market
Description
Insulin Delivery Devices Market Size, Share & Trends Analysis Report By Product (Reusable Insulin Pens, Disposable Insulin Pens), By End Use (Hospitals & Clinics, Homecare), By Region, And Segment Forecasts, 2026 - 2033
Insulin Delivery Devices Market Summary
The global insulin delivery devices market size was estimated at USD 19.3 billion in 2025 and is expected to reach USD 35.2 billion by 2033, growing at a CAGR of 7.8% from 2026 to 2033. The growth is largely attributed to the rising global prevalence of diabetes, which has heightened the demand for advanced and user-friendly solutions for diabetes management.
Technological advancements play a crucial role in the market growth, with the development of devices that are more effective, less invasive, and tailored to meet patients' individual needs. Furthermore, integrating digital technology with insulin delivery devices is expected to boost market growth. This includes the rise of Continuous Glucose Monitoring (CGM) systems that work in tandem with insulin delivery devices to provide real-time glucose monitoring and automated insulin adjustments.
Technological advancements in diabetes management have significantly transformed insulin delivery methods, evolving from traditional injections to more advanced, minimally invasive techniques. Initially, insulin administration faced challenges in maintaining consistent blood glucose levels. However, the advent of insulin pens facilitated easier self-administration, reducing discomfort. The development of insulin pumps allowed for continuous insulin infusion, enhancing glucose control. A pivotal advancement was the introduction of Continuous Glucose Monitoring (CGM) devices, providing real-time glucose data, essential for informed decision-making. This set the stage for Artificial Pancreas Systems (APS), which integrate CGM data with insulin pumps for automated delivery, closely mimicking natural pancreatic function.
Bionic technology, blending biological and artificial processes, has been instrumental in advancing insulin delivery. It underpins devices such as APS, utilizing algorithms, sensors, and automated pumps for precise blood sugar regulation, minimizing manual intervention. These innovations offer tailored, user-friendly solutions, notably improving patient outcomes. Modern insulin pumps, equipped with CGM integration, predictive algorithms, and smartphone connectivity, exemplify significant progress in device functionality, offering accurate and adaptable insulin management. These features not only mitigate risks associated with blood glucose extremes but also empower users with finer control over their insulin dosing, responding dynamically to glucose level changes.
The increasing adoption of connected diabetes management solutions is transforming the way insulin therapy is monitored and administered, with a strong focus on improving patient adherence and clinical outcomes. For instance, in December 2024, a study published by MDPI highlighted that the use of smart insulin pens integrated with continuous glucose monitoring (CGM) in pregnant women with type 1 diabetes, demonstrating improved glycemic control and increased time-in-range without severe hypoglycemia. The system enabled automatic tracking of insulin dose timing and quantity, along with real-time data sharing through a connected mobile application. This development highlights the growing role of connected insulin pen technologies in enhancing adherence and optimizing diabetes management outcomes.
Furthermore, the industry is witnessing a shift towards wearable devices, such as insulin pumps and insulin patch pumps, which offer continuous insulin infusion in a convenient and discreet manner. For instance, in January 2024, PharmaSens, a Switzerland-based company specializing in medical devices, has recently applied for FDA approval in the United States for its 'niia essential' insulin patch pump system. This application represents a pivotal step for PharmaSens in the evolution of insulin pump technologies. Furthermore, the company achieved ISO 13485 certification in November 2023, encompassing the design, development, manufacturing, and distribution of insulin infusion pumps and their accessories. PharmaSens has positioned its product as focused on patient needs and ease of use. Furthermore, in January 2024, Embecta Corp. declared that it had submitted a 510(k) premarket application to the U.S. Food and Drug Administration (FDA) for its unique disposable insulin delivery system.
The development of smart insulin pens, which can track and share dosage data, represents another significant trend, as does the progression towards bionic and artificial pancreas systems that more closely mimic the natural insulin delivery of a healthy pancreas. For instance, in July 2025, Byram Healthcare highlighted advancements in diabetes technology, noting that automated insulin delivery (AID) systems such as patch pumps and integrated devices significantly improved glycemic control, with clinical studies showing reductions in HbA1c levels and increased time-in-range. These systems combine insulin delivery with real-time glucose monitoring and smartphone connectivity, enhancing data tracking and patient management. This development reflects the broader trend toward connected, intelligent diabetes care solutions that mimic natural pancreatic function.
The rising geriatric population is fueling the industry. These devices, such as insulin pens, pumps, and smart insulin devices, cater specifically to the needs of older adults by simplifying the insulin administration process, which can be particularly challenging due to age-related factors such as reduced vision, skill, and cognitive function. The ease of use, dosing accuracy, and the ability to integrate with digital health platforms for monitoring and reminders ensure better adherence to treatment regimens, thereby improving glycemic control & reducing the risk of complications. Given the increasing prevalence of diabetes among older adults globally, the growth potential within this demographic is substantial.
Global Insulin Delivery Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global insulin delivery devices market report on the basis of product, end use, and region:
Insulin Delivery Devices Market Summary
The global insulin delivery devices market size was estimated at USD 19.3 billion in 2025 and is expected to reach USD 35.2 billion by 2033, growing at a CAGR of 7.8% from 2026 to 2033. The growth is largely attributed to the rising global prevalence of diabetes, which has heightened the demand for advanced and user-friendly solutions for diabetes management.
Technological advancements play a crucial role in the market growth, with the development of devices that are more effective, less invasive, and tailored to meet patients' individual needs. Furthermore, integrating digital technology with insulin delivery devices is expected to boost market growth. This includes the rise of Continuous Glucose Monitoring (CGM) systems that work in tandem with insulin delivery devices to provide real-time glucose monitoring and automated insulin adjustments.
Technological advancements in diabetes management have significantly transformed insulin delivery methods, evolving from traditional injections to more advanced, minimally invasive techniques. Initially, insulin administration faced challenges in maintaining consistent blood glucose levels. However, the advent of insulin pens facilitated easier self-administration, reducing discomfort. The development of insulin pumps allowed for continuous insulin infusion, enhancing glucose control. A pivotal advancement was the introduction of Continuous Glucose Monitoring (CGM) devices, providing real-time glucose data, essential for informed decision-making. This set the stage for Artificial Pancreas Systems (APS), which integrate CGM data with insulin pumps for automated delivery, closely mimicking natural pancreatic function.
Bionic technology, blending biological and artificial processes, has been instrumental in advancing insulin delivery. It underpins devices such as APS, utilizing algorithms, sensors, and automated pumps for precise blood sugar regulation, minimizing manual intervention. These innovations offer tailored, user-friendly solutions, notably improving patient outcomes. Modern insulin pumps, equipped with CGM integration, predictive algorithms, and smartphone connectivity, exemplify significant progress in device functionality, offering accurate and adaptable insulin management. These features not only mitigate risks associated with blood glucose extremes but also empower users with finer control over their insulin dosing, responding dynamically to glucose level changes.
The increasing adoption of connected diabetes management solutions is transforming the way insulin therapy is monitored and administered, with a strong focus on improving patient adherence and clinical outcomes. For instance, in December 2024, a study published by MDPI highlighted that the use of smart insulin pens integrated with continuous glucose monitoring (CGM) in pregnant women with type 1 diabetes, demonstrating improved glycemic control and increased time-in-range without severe hypoglycemia. The system enabled automatic tracking of insulin dose timing and quantity, along with real-time data sharing through a connected mobile application. This development highlights the growing role of connected insulin pen technologies in enhancing adherence and optimizing diabetes management outcomes.
Furthermore, the industry is witnessing a shift towards wearable devices, such as insulin pumps and insulin patch pumps, which offer continuous insulin infusion in a convenient and discreet manner. For instance, in January 2024, PharmaSens, a Switzerland-based company specializing in medical devices, has recently applied for FDA approval in the United States for its 'niia essential' insulin patch pump system. This application represents a pivotal step for PharmaSens in the evolution of insulin pump technologies. Furthermore, the company achieved ISO 13485 certification in November 2023, encompassing the design, development, manufacturing, and distribution of insulin infusion pumps and their accessories. PharmaSens has positioned its product as focused on patient needs and ease of use. Furthermore, in January 2024, Embecta Corp. declared that it had submitted a 510(k) premarket application to the U.S. Food and Drug Administration (FDA) for its unique disposable insulin delivery system.
The development of smart insulin pens, which can track and share dosage data, represents another significant trend, as does the progression towards bionic and artificial pancreas systems that more closely mimic the natural insulin delivery of a healthy pancreas. For instance, in July 2025, Byram Healthcare highlighted advancements in diabetes technology, noting that automated insulin delivery (AID) systems such as patch pumps and integrated devices significantly improved glycemic control, with clinical studies showing reductions in HbA1c levels and increased time-in-range. These systems combine insulin delivery with real-time glucose monitoring and smartphone connectivity, enhancing data tracking and patient management. This development reflects the broader trend toward connected, intelligent diabetes care solutions that mimic natural pancreatic function.
The rising geriatric population is fueling the industry. These devices, such as insulin pens, pumps, and smart insulin devices, cater specifically to the needs of older adults by simplifying the insulin administration process, which can be particularly challenging due to age-related factors such as reduced vision, skill, and cognitive function. The ease of use, dosing accuracy, and the ability to integrate with digital health platforms for monitoring and reminders ensure better adherence to treatment regimens, thereby improving glycemic control & reducing the risk of complications. Given the increasing prevalence of diabetes among older adults globally, the growth potential within this demographic is substantial.
Global Insulin Delivery Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global insulin delivery devices market report on the basis of product, end use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Insulin Pens
- Reusable Insulin Pens
- Disposable Insulin Pens
- Insulin Pumps
- Tubed Pumps
- Reusable Device/Components
- Consumables
- Tubeless Insulin Pumps
- Reusable Device/Components
- Consumables
- Insulin Pen Needles
- Standard Pen Needles
- Safety Pen Needles
- Insulin Syringes
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Homecare
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. End Use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. End use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Insulin Delivery Devices Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rise in the prevalence of diabetes globally
- 3.2.1.2. Increasing geriatric population
- 3.2.1.3. Favorable government reimbursement scenario
- 3.2.1.4. Increasing awareness about diabetes preventive care
- 3.2.2. Market restraint analysis
- 3.2.2.1. Stringent regulatory framework
- 3.2.2.2. High cost of devices
- 3.3. Insulin Delivery Devices Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Insulin Delivery Devices Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Insulin Delivery Devices Product Market Movement Analysis
- 4.3. Global Insulin Delivery Devices Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Insulin Pens
- 4.4.1. Insulin pens market estimates and forecasts 2021 to 2033 (USD Million)
- 4.4.2. Reusable Insulin Pens
- 4.4.2.1. Reusable insulin pens market estimates and forecasts 2021 to 2033 (USD Million)
- 4.4.3. Disposable Insulin Pens
- 4.4.3.1. Disposable insulin pens market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Insulin Pumps
- 4.5.1. Insulin pumps market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5.2. Tubed Pumps
- 4.5.2.1. Tubed pumps market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5.2.2. Reusable Device/Components
- 4.5.2.2.1. Reusable Device/Components market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5.2.3. Consumables
- 4.5.2.3.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5.3. Tubeless Insulin Pumps
- 4.5.3.1. Tubeless insulin pumps market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5.3.2. Reusable Device/Components
- 4.5.3.2.1. Reusable Device/Components market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5.3.3. Consumables
- 4.5.3.3.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. Insulin Pen Needles
- 4.6.1. Insulin pen needles market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6.2. Standard Pen Needles
- 4.6.2.1. Standard pen needles market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6.3. Safety Pen Needles
- 4.6.3.1. Safety pen needles market estimates and forecasts 2021 to 2033 (USD Million)
- 4.7. Insulin Syringes
- 4.7.1. Insulin syringes market estimates and forecasts 2021 to 2033 (USD Million)
- 4.8. Others
- 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 5. Insulin Delivery Devices Market: End Use Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Insulin Delivery Devices End Use Market Movement Analysis
- 5.3. Global Insulin Delivery Devices Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 5.4. Hospitals & Clinics
- 5.4.1. Hospitals & clinics market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Homecare
- 5.5.1. Homecare market estimates and forecasts 2021 to 2033 (USD Million)
- 5.6. Others
- 5.6.1. Other market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 6. Insulin Delivery Devices Market: Regional Estimates & Trend Analysis By Product, End Use
- 6.1. Regional Market Share Analysis, 2025 & 2033
- 6.2. Regional Market Dashboard
- 6.3. Global Regional Market Snapshot
- 6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 6.5. North America
- 6.5.1. U.S.
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Competitive scenario
- 6.5.1.3. Regulatory framework
- 6.5.1.4. Reimbursement structure
- 6.5.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.2. Canada
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Competitive scenario
- 6.5.2.3. Regulatory framework
- 6.5.2.4. Reimbursement structure
- 6.5.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.3. Mexico
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Competitive scenario
- 6.5.3.3. Regulatory framework
- 6.5.3.4. Reimbursement structure
- 6.5.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6. Europe
- 6.6.1. UK
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Competitive scenario
- 6.6.1.3. Regulatory framework
- 6.6.1.4. Reimbursement structure
- 6.6.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.2. Germany
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Competitive scenario
- 6.6.2.3. Regulatory framework
- 6.6.2.4. Reimbursement structure
- 6.6.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.3. France
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Competitive scenario
- 6.6.3.3. Regulatory framework
- 6.6.3.4. Reimbursement structure
- 6.6.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.4. Italy
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Competitive scenario
- 6.6.4.3. Regulatory framework
- 6.6.4.4. Reimbursement structure
- 6.6.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.5. Spain
- 6.6.5.1. Key country dynamics
- 6.6.5.2. Competitive scenario
- 6.6.5.3. Regulatory framework
- 6.6.5.4. Reimbursement structure
- 6.6.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.6. Norway
- 6.6.6.1. Key country dynamics
- 6.6.6.2. Competitive scenario
- 6.6.6.3. Regulatory framework
- 6.6.6.4. Reimbursement structure
- 6.6.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.7. Sweden
- 6.6.7.1. Key country dynamics
- 6.6.7.2. Competitive scenario
- 6.6.7.3. Regulatory framework
- 6.6.7.4. Reimbursement structure
- 6.6.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.8. Denmark
- 6.6.8.1. Key country dynamics
- 6.6.8.2. Competitive scenario
- 6.6.8.3. Regulatory framework
- 6.6.8.4. Reimbursement structure
- 6.6.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7. Asia Pacific
- 6.7.1. Japan
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Competitive scenario
- 6.7.1.3. Regulatory framework
- 6.7.1.4. Reimbursement structure
- 6.7.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.2. China
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Competitive scenario
- 6.7.2.3. Regulatory framework
- 6.7.2.4. Reimbursement structure
- 6.7.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.3. India
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Competitive scenario
- 6.7.3.3. Regulatory framework
- 6.7.3.4. Reimbursement structure
- 6.7.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.4. Australia
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Competitive scenario
- 6.7.4.3. Regulatory framework
- 6.7.4.4. Reimbursement structure
- 6.7.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.5. South Korea
- 6.7.5.1. Key country dynamics
- 6.7.5.2. Competitive scenario
- 6.7.5.3. Regulatory framework
- 6.7.5.4. Reimbursement structure
- 6.7.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.6. Thailand
- 6.7.6.1. Key country dynamics
- 6.7.6.2. Competitive scenario
- 6.7.6.3. Regulatory framework
- 6.7.6.4. Reimbursement structure
- 6.7.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8. Latin America
- 6.8.1. Brazil
- 6.8.1.1. Key country dynamics
- 6.8.1.2. Competitive scenario
- 6.8.1.3. Regulatory framework
- 6.8.1.4. Reimbursement structure
- 6.8.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8.2. Argentina
- 6.8.2.1. Key country dynamics
- 6.8.2.2. Competitive scenario
- 6.8.2.3. Regulatory framework
- 6.8.2.4. Reimbursement structure
- 6.8.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9. MEA
- 6.9.1. South Africa
- 6.9.1.1. Key country dynamics
- 6.9.1.2. Competitive scenario
- 6.9.1.3. Regulatory framework
- 6.9.1.4. Reimbursement structure
- 6.9.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.2. Saudi Arabia
- 6.9.2.1. Key country dynamics
- 6.9.2.2. Competitive scenario
- 6.9.2.3. Regulatory framework
- 6.9.2.4. Reimbursement structure
- 6.9.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.3. UAE
- 6.9.3.1. Key country dynamics
- 6.9.3.2. Competitive scenario
- 6.9.3.3. Regulatory framework
- 6.9.3.4. Reimbursement structure
- 6.9.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.4. Kuwait
- 6.9.4.1. Key country dynamics
- 6.9.4.2. Competitive scenario
- 6.9.4.3. Regulatory framework
- 6.9.4.4. Reimbursement structure
- 6.9.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Key company market share analysis, 2025
- 7.4. Company Position Analysis
- 7.5. Company Categorization (Emerging Players, Innovators and Leaders
- 7.6. Company Profiles
- 7.6.1. Novo Nordisk A/S
- 7.6.1.1. Company overview
- 7.6.1.2. Financial performance
- 7.6.1.3. Product benchmarking
- 7.6.1.4. Strategic initiatives
- 7.6.2. Sanofi
- 7.6.2.1. Company overview
- 7.6.2.2. Financial performance
- 7.6.2.3. Product benchmarking
- 7.6.2.4. Strategic initiatives
- 7.6.3. Eli Lilly and Company
- 7.6.3.1. Company overview
- 7.6.3.2. Financial performance
- 7.6.3.4. Strategic initiatives
- 7.6.4. Ypsomed AG
- 7.6.4.1. Company overview
- 7.6.4.2. Financial performance
- 7.6.4.3. Product benchmarking
- 7.6.4.4. Strategic initiatives
- 7.6.5. Medtronic
- 7.6.5.1. Company overview
- 7.6.5.2. Financial performance
- 7.6.5.3. Product benchmarking
- 7.6.5.4. Strategic initiatives
- 7.6.6. Insulet Corporation
- 7.6.6.1. Company overview
- 7.6.6.2. Financial performance
- 7.6.6.3. Product benchmarking
- 7.6.6.4. Strategic initiatives
- 7.6.7. B. Braun SE
- 7.6.7.1. Company overview
- 7.6.7.2. Financial performance
- 7.6.7.3. Product benchmarking
- 7.6.7.4. Strategic initiatives
- 7.6.8. Owen Mumford Ltd.
- 7.6.8.1. Company overview
- 7.6.8.2. Financial performance
- 7.6.8.3. Product benchmarking
- 7.6.8.4. Strategic initiatives
- 7.6.9. Tandem Diabetes Care, Inc.
- 7.6.9.1. Company overview
- 7.6.9.2. Financial performance
- 7.6.9.3. Product benchmarking
- 7.6.9.4. Strategic initiatives
- 7.6.9.5. Company overview
- 7.6.10. BD (Becton, Dickinson and Company)
- 7.6.10.1. Company overview
- 7.6.10.2. Financial performance
- 7.6.10.3. Product benchmarking
- 7.6.10.4. Strategic initiatives
- 7.6.10.5. Company overview
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
